Table 3. - boceprevir or telaprevir therapeutic regimen outcomes.
| boceprevir (n=247) | telaprevir (n=608) | P valuea,b | |||
|---|---|---|---|---|---|
| n | % | n | % | ||
| SVRc | 99 | 45.6 | 273 | 51.8 | 0.125 |
| No responder | 48 | 19.4 | 122 | 20.0 | 0.104 |
| Abandonment | 11 | 4.5 | 23 | 3.8 | 0.649 |
| Relapsec | 37 | 17.0 | 61 | 11.6 | 0.050 |
| Discontinuation due to AEs | 38 | 15.4 | 77 | 12.7 | 0.291 |
| Hematologic eventsd | 18 | 7.3 | 38 | 6.3 | 0.689 |
| Cutaneous reactionse | 3 | 1.2 | 19 | 3.1 | 0.117 |
| Others eventsf | 17 | 6.9 | 23 | 3.8 | 0.077 |
| Dead | 3 | 1.2 | 8 | 1.3 | 0.905 |
SVR: sustained virological response. AEs: adverse events. aChi square test. bFisher’s exact test. cMissing (n): SVR and relapse (111), partial responders (25). dHematologic events considered: anemia, neutropenia, thrombocytopenia, bleeding and thrombosis. eCutaneous reactions considered: rush, pruritus and dry skin. fOther events considered: renal dysfunction, liver imbalance, sepsis, peripheral neuropathy, psychiatric disorders. The total number of outcomes for telaprevir and boceprevir are higher due the same patient may present more than one outcome